Guidelines on Radioisotope Treatment of Lymphomas

Chapter

Abstract

The present chapter has the aim to provide the current position of radioimmunotherapy for the treatment of lymphoma, in the main national and international clinical guidelines. In Table 33.1, a summary of clinical indications is reported.

References

  1. 1.
    Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the diagnosis and management of lymphoma. The Cancer Council Australia and Australian Cancer Network, Sydney. 2005.Google Scholar
  2. 2.
    Tennvall J, Fischer M, Delaloye AB, Bombardieri E, Bodei L, Giammarile F, Lassmann M, Oyen W, Brans B, Therapy Committee EANM, Oncology Committee EANM, Dosimetry Committee EANM. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomabtiuxetan (Zevalin®). Eur J Nucl Med Mol Imaging. 2007;34(4):616–22.CrossRefPubMedGoogle Scholar
  3. 3.
    London cancer north and east. London cancer guidelines for the management of lymphoma. June 2014; available from the link: https://londoncancer.org.
  4. 4.
    Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, LeGouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):83–92.CrossRefGoogle Scholar
  5. 5.
    Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M, on behalf of the ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):116–25.CrossRefGoogle Scholar
  6. 6.
    Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, on behalf of the ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):63–90.Google Scholar
  7. 7.
    Balzarotti M, Carbone A, Castagna L, Pinotti G, Ricardi U, Spina M, Tedeschi L, AIOM Linee Guida Linfomi. 2016; available from the link: http://www.aiom.it/professionisti/documenti-scientifici/linee-guida/1,413,1,#TopList.
  8. 8.
    NCCN guidelines version 3.2017; available from the link: http://www.nccn.org.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical-Surgical Sciences and Translational Medicine“Sapienza” UniversityRomeItaly
  2. 2.Nuclear Medicine and Molecular Imaging UnitVeneto Institute of Oncology IOV – IRCCSPaduaItaly

Personalised recommendations